Guggenheim Capital LLC Bei Gene, Ltd. Transaction History

Guggenheim Capital LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$146.52 - $269.56 $113,846 - $209,448	-777 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$248.56 - $389.34 $1.62 Million - $2.53 Million	-6,499 Reduced 89.32%	777 $211,000
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $331,219 - $534,966	-1,327 Reduced 15.42%	7,276 $2.64 Million
Q2 2021 Aug 13, 2021	BUY	$292.75 - $367.01 $198,191 - $248,465	677 Added 8.54%	8,603 $2.95 Million
Q1 2021 May 13, 2021	SELL	$260.64 - $382.12 $798,600 - $1.17 Million	-3,064 Reduced 27.88%	7,926 $2.76 Million
Q4 2020 Feb 16, 2021	BUY	$221.31 - $316.61 $975,534 - $1.4 Million	4,408 Added 66.97%	10,990 $2.84 Million
Q3 2020 Nov 13, 2020	SELL	$189.18 - $286.44 $1.87 Million - $2.82 Million	-9,862 Reduced 59.97%	6,582 $1.89 Million
Q2 2020 Aug 14, 2020	BUY	$123.9 - $195.41 $303,926 - $479,340	2,453 Added 17.53%	16,444 $3.1 Million
Q1 2020 Jun 02, 2020	SELL	$121.84 - $173.19 $357,600 - $508,312	-2,935 Reduced 17.34%	13,991 $1.72 Million
Q4 2019 Feb 14, 2020	BUY	$115.78 - $208.34 $1.96 Million - $3.53 Million	16,926 New	16,926 $2.81 Million
Q2 2018 Aug 14, 2018	SELL	$152.5 - $216.77 $851,407 - $1.21 Million	-5,583 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$97.41 - $177.22 $54,354 - $98,888	558 Added 11.1%	5,583 $938,000
Q4 2017 Feb 14, 2018	SELL	$79.6 - $114.73 $1.09 Million - $1.57 Million	-13,675 Reduced 73.13%	5,025 $491,000
Q3 2017 Nov 14, 2017	BUY	$66.19 - $103.46 $1.24 Million - $1.93 Million	18,700	18,700 $1.94 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.